After reporting that a mid-stage clinical trial stumbled, NewLink Genetics Corporation (NASDAQ: NLNK) shares lost 10.3% of their value today.Last year, attention shifted to NewLink's IDO-inhibiting cancer drug pipeline after its once-promising algenpantucel-L failed to achieve its primary endpoint in phase 3 trials.IMAGE SOURCE: GETTY IMAGES.Continue reading